Biomarkers of altered coagulation and fibrinolysis as measures of disease activity in active inflammatory bowel disease: A gender-stratified, cohort analysis

Thrombosis Research

Volumn 123, Issue 4, 2009, Pages 604-611

  Shen, Jun ^a   Ran, Zhi Hua ^a   Zhang, Yao ^a   Cai, Qing ^a   Yin, Hong Min ^a   Zhou, Xiao Tian ^a   Xiao, Shu Dong ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

Coagulation and fibrinolysis status; Crohn's disease; Disease activity; Ulcerative colitis

Indexed keywords

BIOLOGICAL MARKER; FIBRINOGEN;

ADULT; ARTICLE; BLOOD CLOTTING DISORDER; CONTROLLED STUDY; CROHN DISEASE; DISEASE ACTIVITY; ENTERITIS; FEMALE; FIBRINOLYSIS; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE; THROMBOCYTE VOLUME; THROMBOPLASTIN TIME; ULCERATIVE COLITIS;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD PLATELETS; COHORT STUDIES; FEMALE; FIBRINOGEN; FIBRINOLYSIS; HUMANS; INFLAMMATORY BOWEL DISEASES; MALE; MIDDLE AGED; PROTHROMBIN TIME; SEX FACTORS;

EID: 58949099542     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2008.04.004     Document Type: Article

References (42)

1. Suárez Crespo J.F., Nogueras López F., de Teresa Galván F.J., de Sola Earle C.M., González Galilea A., Pinel Julián L.M., et al. Thromboembolic complications in inflammatory bowel disease. Gastroenterol Hepatol 20 (1997) 180-183
2. Novacek G., Haumer M., Schima W., Müller C., Miehsler W., Polterauer P., et al. Aortic mural thrombi in patients with inflammatory bowel disease: report of two cases and review of the literature. Inflamm Bowel Dis 10 (2004) 430-435
3. Larsen T.B., Nielsen J.N., Fredholm L., Lund E.D., Brandslund I., Munkholm P., et al. Platelets and anticoagulant capacity in patients with inflammatory bowel disease. Pathophysiol Haemost Thromb 32 (2002) 92-96
4. Bouma B.N., and Mosnier L.O. Thrombin activatable fibrinolysis inhibitor (TAFI) at the interface between coagulation and fibrinolysis. Pathophysiol Haemost Thromb 33 (2004) 375-381
5. Shinozawa Y., Xie X.Q., Endo T., Takuma K., and Koike K. Correlation between intravascular coagulation/fibrinolysis system and cytokines. Nippon Rinsho 62 (2004) 2253-2261
6. Folwaczny C. Coagulation system and inflammatory bowel disease: therapeutic and pathophysiologic implications. Z Gastroenterol 40 (2002) 991-998
7. Kjeldsen J., Lassen J.F., Brandslund I., and Schaffalitzky de Muckadell O.B. Markers of coagulation and fibrinolysis as measures of disease activity in inflammatory bowel disease. Scand J Gastroenterol 33 (1998) 637-643
8. Esmon C.T. Crosstalk between inflammation and thrombosis. Maturitas 47 (2004) 305-314
9. Esmon C.T. Coagulation and inflammation. J Endotoxin Res 9 (2003) 192-198
10. Grignani G., and Maiolo A. Cytokines and hemostasis. Haematologica 85 (2000) 967-972
11. Cavaillon J.M. Cytokines in inflammation. C R Seances Soc Biol Fil 189 (1995) 531-544
12. Emerson Jr. T.E., Fournel M.A., Redens T.B., and Taylor Jr. F.B. Efficacy of antithrombin III supplementation in animal models of fulminant Escherichia coli endotoxemia or bacteremia. Am J Med 87 (1989) 27S-33S
13. Creasey A.A., Chang A.C., Feigen L., Wün T.C., Taylor Jr. F.B., and Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J Clin Invest 91 (1993) 2850-2860
14. Irving P.M., Pasi K.J., and Rampton D.S. Thrombosis and inflammatory bowel disease. Clin Gastroenterol Hepatol 3 (2005) 617-628
15. van Bodegraven A.A. Haemostasis in inflammatory bowel diseases: clinical relevance. Scand J Gastroenterol 239 suppl (2003) 51-62
16. Hayat M., Ariëns R.A., Moayyedi P., Grant P.J., and O'Mahony S. Coagulation factor XIII and markers of thrombin generation and fibrinolysis in patients with inflammatory bowel disease. Eur J Gastroenterol Hepatol 14 (2002) 249-256
17. Saibeni S., Bottasso B., Spina L., Bajetta M., Danese S., Gasbarrini A., et al. Assessment of thrombin-activatable fibrinolysis inhibitor (TAFI) plasma levels in inflammatory bowel diseases. Am J Gastroenterol 99 (2004) 1966-1970
18. Kume K., Yamasaki M., Tashiro M., Yoshikawa I., and Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 46 (2007) 1323-1329
19. Sikka M., Tandon R., Rusia U., and Madan N. Validation of ESR analyzer using Westergren ESR method. Indian J Pathol Microbiol 50 (2007) 634-635
20. Walmsley R.S., Ayres R.C., Pounder R.E., and Allan R.N. A simple clinical colitis activity index. Gut 43 (1998) 29-32
21. Baron J.H., Connell A.M., and Lennard J.E. Variation between observers in describing mucosal appearances in proctocolitis. Br Med J 1 (1964) 89-92
22. Harvey R.F., and Bradshaw J.M. A simple index of Crohn's-disease activity. Lancet 1 (1980) 514
23. Sostegni R., Daperno M., Scaglione N., Lavagna A., Rocca R., and Pera A. Review article: Crohn's disease: monitoring disease activity. Aliment Pharmacol Ther 17 Suppl 2 (2003) 11-17
24. Ediger J.P., Walker J.R., Graff L., Lix L., Clara I., Rawsthorne P., et al. Predictors of medication adherence in inflammatory bowel disease. Am J Gastroenterol 102 (2007) 1417-1426
25. Bernstein C.N., Blanchard J.F., Houston D., and Wajda A. The incidence of venous thromboembolic disease among patients with IBD: a population-based study. Thromb Haemost 85 (2001) 430-434
26. Srirajaskanthan R., Winter M., and Muller A.F. Venous thrombosis in inflammatory bowel disease. Eur J Gastroenterol Hepatol 17 (2005) 697-700
27. Weber P., Husemann S., Vielhaber H., Zimmer K.P., and Nowak-Göttl U. Coagulation and fibrinolysis in children, adolescents, and young adults with inflammatory bowel disease. J Pediatr Gastroenterol Nutr 28 (1999) 418-422
28. Swiatkowski M., Grad K., Kłopocka M., Budzyński J., Zekanowska E., and Kotschy M. Blood coagulation activation in patients with ulcerative colitis. Pol Arch Med Wewn 103 (2000) 47-51
29. Wang Y.F., Zhang H., and Ouyang Q. Clinical manifestations of inflammatory bowel disease: East and West differences. J Dig Dis 8 (2007) 121-127
30. van Wersch J.W., Houben P., and Rijken J. Platelet count, platelet function, coagulation activity and fibrinolysis in the acute phase of inflammatory bowel disease. J Clin Chem Clin Biochem 28 (1990) 513-517
31. Harries A.D., Beeching N.J., Rogerson S.J., and Nye F.J. The platelet count as a simple measure to distinguish inflammatory bowel disease from infective diarrhoea. J Infect 22 (1991) 247-250
32. Cabrera-Abreu J.C., Davies P., Matek Z., and Murphy M.S. Performance of blood tests in diagnosis of inflammatory bowel disease in a specialist clinic. Arch Dis Child 89 (2004) 69-71
33. Collins C.E., and Rampton D.S. Review article: platelets in inflammatory bowel disease-pathogenetic role and therapeutic implications. Aliment Pharmacol Ther 11 (1997) 237-247
34. Schaufelberger H.D., Uhr M.R., McGuckin C., Logan R.P., Misiewicz J.J., Gordon-Smith E.C., et al. Platelets in ulcerative colitis and Crohn's disease express functional interleukin-1 and interleukin-8 receptors. Eur J Clin Invest 24 (1994) 656-663
35. Douda T., Bures J., Rejchrt S., Kopácová M., Pecka M., and Malý J. Mean platelet volume (MPV) in Crohn's disease patients. Cas Lek Cesk 145 (2006) 870-873
36. Chiarantini E., Valanzano R., Liotta A.A., Cellai A.P., Fedi S., Ilari I., et al. Hemostatic abnormalities in inflammatory bowel disease. Thromb Res 82 (1996) 137-146
37. Payzin B., Adakan F.Y., Yalçin H.C., Cetinkaya G.S., Berkmen S., Eraslan S., et al. Natural coagulation inhibitory proteins and activated protein C resistance in Turkish patients with inflammatory bowel disease. Turk J Gastroenterol 17 (2006) 183-190
38. Kume K., Yamasaki M., Tashiro M., Yoshikawa I., and Otsuki M. Activations of coagulation and fibrinolysis secondary to bowel inflammation in patients with ulcerative colitis. Intern Med 46 (2007) 1323-1329
39. Heiden M., Seitz R., and Egbring R. The role of inflammatory cells and their proteases in extravascular fibrinolysis. Semin Thromb Hemost 22 (1996) 497-501
40. Parry G.C., Erlich J.H., Carmeliet P., Luther T., and Mackman N. Low levels of tissue factor are compatible with development and hemostasis in mice. J Clin Invest 101 (1998) 560-569
41. Lindmark E., Tenno T., and Siegbahn A. Role of platelet P-selectin and CD40 ligand in the induction of monocytic tissue factor expression. Arterioscler Thromb Vasc Biol 20 (2000) 2322-2328
42. Kovar F.M., Marsik C., Jilma B., Mannhalter C., Quehenberger P., Handler S., et al. The fibrinogen - 148 C/T polymorphism influences inflammatory response in experimental endotoxemia in vivo. Thromb Res 120 (2007) 727-731